tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Multiple Pulmonary Nodules D055613 2 associated lipids
Central Serous Chorioretinopathy D056833 1 associated lipids
Malocclusion, Angle Class II D008312 1 associated lipids
Retrognathia D063173 1 associated lipids
Leg Injuries D007869 2 associated lipids
Aneurysm, Dissecting D000784 2 associated lipids
Granulomatosis, Orofacial D051261 2 associated lipids
Eye Diseases, Hereditary D015785 1 associated lipids
Pruritus Ani D011538 2 associated lipids
AIDS-Associated Nephropathy D016263 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Manuyakorn W et al. In vitro cytokine changes after pediatric liver transplantation. 2015 Asian Pac. J. Allergy Immunol. pmid:25840634
Li T et al. Effect of FK506 nanospheres on regeneration of allogeneic nerve after transplant. 2014 Asian Pac J Trop Med pmid:25066398
Dai YJ et al. Effect of pharmacological intervention on MIP-1α, MIP-1β and MCP-1 expression in patients with psoriasis vulgaris. 2014 Asian Pac J Trop Med pmid:25063291
Ogita K et al. Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report. 2003 Asian J Surg pmid:14530108
Cacciarelli TV et al. Influence of the timing of FK 506 (Tacrolimus) administration on recovery of renal function from warm ischemic injury in rats. 1994 Oct-Dec ASAIO J. pmid:7532042
Tsubo T et al. Elimination of FK-506 by continuous hemodiafiltration in a liver transplant patient. 1997 Jul-Aug ASAIO J. pmid:9242954
Imanishi Y et al. Pharmacokinetic properties of a once-daily formulation of tacrolimus in patients with renal transplantation. 2011 Arzneimittelforschung pmid:21528645
Takayama T et al. Effects of the novel and potent lymphocyte-specific protein tyrosine kinase inhibitor TKM0150 on mixed lymphocyte reaction and contact hypersensitivity in mice. 2010 Arzneimittelforschung pmid:20533766
Lainesse A et al. Bioequivalence studies of tacrolimus capsule under fasting and fed conditions in healthy male and female subjects. 2008 Arzneimittelforschung pmid:18589558
Haehner T et al. Drug-drug interactions evaluated by a highly active reconstituted native human cytochrome P4503A4 and human NADPH-cytochrome P450 reductase system. 2004 Arzneimittelforschung pmid:14979613
Marcelín-Jiménez G et al. Development of an ultra-performance liquid chromatography technique coupled with mass spectrometry for the measurement of tacrolimus in micro-samples of whole blood, and its application on a pharmacokiinetic trial. 2007 Arzneimittelforschung pmid:18074760
Iwasaki K et al. Effect of repeated oral doses of a novel immunosuppressive macrolide lactone on hepatic mixed-function oxidase system in the rat. Comparative study with ciclosporin. 1992 Arzneimittelforschung pmid:1379812
Dawson S et al. UCLA liver transplantation: analysis of immunological factors affecting outcome. 1996 Artif Organs pmid:8896726
Kashu Y et al. Prolongation of rat liver graft survival by splenectomy combined with low dose FK506 therapy. 1996 Artif Organs pmid:8896731
Ohshima S et al. Immunosuppressive treatment of primary cadaveric renal transplant patients receiving kidneys from non-heart beating donors. 1996 Artif Organs pmid:8896734
Wada Y et al. BCX-34: a novel T-cell selective immunosuppressant: purine nucleoside phosphorylase (PNP) inhibitor. 1996 Artif Organs pmid:8853794
Haisheng H et al. Assessment of nerve regeneration across nerve allografts treated with tacrolimus. 2008 Artif Cells Blood Substit Immobil Biotechnol pmid:18925465
van der Windt AE et al. Inhibiting calcineurin activity under physiologic tonicity elevates anabolic but suppresses catabolic chondrocyte markers. 2012 Arthritis Rheum. pmid:22231955
Suzuki N et al. In vivo mechanisms for the inhibition of T lymphocyte activation by long-term therapy with tacrolimus (FK-506): experience in patients with Behçet's disease. 1997 Arthritis Rheum. pmid:9182928
de Paulis A et al. Human synovial mast cells. II. Heterogeneity of the pharmacologic effects of antiinflammatory and immunosuppressive drugs. 1997 Arthritis Rheum. pmid:9082935
Cho ML et al. Cyclosporine differentially regulates interleukin-10, interleukin-15, and tumor necrosis factor a production by rheumatoid synoviocytes. 2002 Arthritis Rheum. pmid:11817607
Kremer JM et al. Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study. 2003 Arthritis Rheum. pmid:14558080
Asano Y et al. Differential effects of the immunosuppressant FK-506 on human alpha2(I) collagen gene expression and transforming growth factor beta signaling in normal and scleroderma fibroblasts. 2005 Arthritis Rheum. pmid:15818662
Wilkes MR et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. 2005 Arthritis Rheum. pmid:16052580
Stone JH et al. Outcome of renal transplantation in ninety-seven cyclosporine-era patients with systemic lupus erythematosus and matched controls. 1998 Arthritis Rheum. pmid:9704643
Yocum DE et al. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial. 2003 Arthritis Rheum. pmid:14673984
Furst DE et al. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. 2002 Arthritis Rheum. pmid:12209503
Cho ML et al. Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fibroblasts. 2002 Arthritis Rheum. pmid:12115224
Parker CT and Rennie T Failure to report previously used drugs and dosages in pharmaceutical company-sponsored rheumatoid arthritis trials: comment on the article by Yocum et al. 2004 Arthritis Rheum. pmid:15457479
Migita K et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus. 2015 Arthritis Res. Ther. pmid:26036592
Choe JY et al. Regulatory effect of calcineurin inhibitor, tacrolimus, on IL-6/sIL-6R-mediated RANKL expression through JAK2-STAT3-SOCS3 signaling pathway in fibroblast-like synoviocytes. 2013 Arthritis Res. Ther. pmid:23406906
Long C et al. Removal of FKBP12/12.6 from endothelial ryanodine receptors leads to an intracellular calcium leak and endothelial dysfunction. 2007 Arterioscler. Thromb. Vasc. Biol. pmid:17478757
Ikezoe T et al. Thrombomodulin protects endothelial cells from a calcineurin inhibitor-induced cytotoxicity by upregulation of extracellular signal-regulated kinase/myeloid leukemia cell-1 signaling. 2012 Arterioscler. Thromb. Vasc. Biol. pmid:22796578
Murakami R et al. Cyclosporin A enhances interleukin-8 expression by inducing activator protein-1 in human aortic smooth muscle cells. 2003 Arterioscler. Thromb. Vasc. Biol. pmid:12958044
Vindis C et al. Two distinct calcium-dependent mitochondrial pathways are involved in oxidized LDL-induced apoptosis. 2005 Arterioscler. Thromb. Vasc. Biol. pmid:15618541
Lasa J and Olivera P EFFICACY OF TACROLIMUS FOR INDUCTION OF REMISSION IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS. Arq Gastroenterol pmid:28327826
Müller EG et al. Tacrolimus eye drops as monotherapy for vernal keratoconjunctivitis: a randomized controlled trial. 2017 Arq Bras Oftalmol pmid:28832739
Liendo VL et al. Topical tacrolimus for the treatment of severe allergic keratoconjunctivitis in children. Arq Bras Oftalmol pmid:28954018
Zulim LFDC et al. Comparison of the efficacy of 0.03% tacrolimus eye drops diluted in olive oil and linseed oil for the treatment of keratoconjunctivitis sicca in dogs. Arq Bras Oftalmol pmid:29995121
Carvalho CS et al. [Fibroblasts from recurrent pterygium and normal Tenon's capsule exposed to tacrolimus (FK-506)]. 2007 Mar-Apr Arq Bras Oftalmol pmid:17589693
Nakamura K [Treatment of atopic dermatitis]. 2009 Arerugi pmid:19901507
Saeki H [Brief commentary on guidelines for the management of atopic dermatitis 2012 -the point of drug treatment]. 2013 Arerugi pmid:24608647
Ochiai T [Advances in the fundamentals and therapeutic use of immunosuppressive agents]. 1992 Arerugi pmid:1374229
Teraki Y [Atopic dermatitis in pregnancy]. 2014 Arerugi pmid:24714179
Ebihara N [New strategy in the treatment of vernal keratoconjunctivitis by calcineurin inhibitor eye drops]. 2010 Arerugi pmid:21119297
Akutsu I et al. [Inhibitory effects of cyclosporin A and FK-506 on eosinophil chemotactic factor activity in culture supernatants of mononuclear cells from asthmatics]. 1992 Arerugi pmid:1280086
Yamamoto S [Guidelines for the management of atopic dermatitis 2006]. 2008 Arerugi pmid:19052504
Akutsu I et al. [Inhibitory effect of inhaled FK-506 on increased bronchial responsiveness and eosinophil infiltration in the airway mucosa]. 1992 Arerugi pmid:1377905
Hossain M et al. Effects of various drugs (staurosporine, herbimycin A, ketotifen, theophylline, FK506 and cyclosporin A) on eosinophil viability. 1994 Arerugi pmid:7520689
Takehara K [Treatment of juvenile atopic dermatitis]. 2010 Arerugi pmid:21212728
Akutsu I et al. [Inhibitory effect of FK-506 on the development of late asthmatic response and on the increased bronchial responsiveness]. 1990 Arerugi pmid:1705791
Ohtsuki M [Tacrolimus ointment for the treatment of atopic dermatitis]. 2009 Arerugi pmid:19487830
Nishimoto K et al. [Case of organizing pneumonia associated with sweet's syndrome]. 2014 Arerugi pmid:25163580
Briggs CJ et al. Comparison of the effect of FK506 and cyclosporin A on virus production in H9 cells chronically and newly infected by HIV-1. 1999 Arch. Virol. pmid:10603169
Minder D et al. Immunophilins and HIV-1 infection. 2002 Arch. Virol. pmid:12181673
Ellouk-Achard S et al. Implication of CYP 3A in the toxicity of cyclosporin G (CsG), cyclosporin A (CsA) and FK506 on rat hepatocytes in primary culture. 1997 Arch. Toxicol. pmid:9209689
Aam BB and Fonnum F Carbon black particles increase reactive oxygen species formation in rat alveolar macrophages in vitro. 2007 Arch. Toxicol. pmid:17119925
Kafert-Kasting S et al. Safety assessment of intraportal liver cell application in New Zealand white rabbits under GLP conditions. 2012 Arch. Toxicol. pmid:22532025
Massicot F et al. Modulation of energy status and cytotoxicity induced by FK506 and cyclosporin A in a renal epithelial cell line. 1997 Arch. Toxicol. pmid:9248632
Kimura Y et al. Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. 2018 Arch. Toxicol. pmid:29594315
Vandenbussche C et al. Tacrolimus-induced nephrotoxicity in mice is associated with microRNA deregulation. 2018 Arch. Toxicol. pmid:29362864
Ellouk-Achard S et al. FK506 (Tacrolimus) decreases the cytotoxicity of cyclosporin A in rat hepatocytes in primary culture: implication of CYP3A induction. 1998 Arch. Toxicol. pmid:9630010
Schaap MM et al. A novel toxicogenomics-based approach to categorize (non-)genotoxic carcinogens. 2015 Arch. Toxicol. pmid:25270620
Chung Y and Cho H Preparation of highly water soluble tacrolimus derivatives: poly(ethylene glycol) esters as potential prodrugs. 2004 Arch. Pharm. Res. pmid:15460452
Kwon M et al. Bioequivalence of tacrolimus formulations with different dynamic solubility and in-vitro dissolution profiles. 2015 Arch. Pharm. Res. pmid:24627339
Park YJ et al. Physicochemical characterization of tacrolimus-loaded solid dispersion with sodium carboxylmethyl cellulose and sodium lauryl sulfate. 2009 Arch. Pharm. Res. pmid:19557367
Seo YG et al. Preparation and pharmaceutical evaluation of new tacrolimus-loaded solid self-emulsifying drug delivery system. 2015 Arch. Pharm. Res. pmid:25134927
Park JS et al. A rapid and sensitive method to determine tacrolimus in rat whole blood using liquid-liquid extraction with mild temperature ultrasonication and LC-MS/MS. 2016 Arch. Pharm. Res. pmid:26589688
Choi D and Cho H Effect of tacrolimus derivatives on immunosuppression. 2009 Arch. Pharm. Res. pmid:19407973
Choi D et al. Effects of water-soluble tacrolimus-PEG conjugate on insulin-dependent diabetes mellitus and systemic lupus erythematosus. 2011 Arch. Pharm. Res. pmid:21910052
Hüser N et al. Graft preconditioning with low-dose tacrolimus (FK506) and nitric oxide inhibitor aminoguanidine (AGH) reduces ischemia/reperfusion injury after liver transplantation in the rat. 2009 Arch. Pharm. Res. pmid:19280151
Etzell JE and Wang E Acquired Pelger-Huët anomaly in association with concomitant tacrolimus and mycophenolate mofetil in a liver transplant patient: a case report and review of the literature. 2006 Arch. Pathol. Lab. Med. pmid:16390246
DiGiuseppe JA et al. Tacrolimus-related posttransplant lymphoproliferative disorder presenting as autoimmune hemolytic anemia. 1996 Arch. Pathol. Lab. Med. pmid:8629906
Steele BW et al. A longitudinal replicate study of immunosuppressive drugs: a College of American Pathologists study. 2003 Arch. Pathol. Lab. Med. pmid:12653570
Wang S et al. A fast and simple high-performance liquid chromatography/mass spectrometry method for simultaneous measurement of whole blood tacrolimus and sirolimus. 2005 Arch. Pathol. Lab. Med. pmid:15859639
Gorgan M et al. Pulmonary hemorrhage with capillaritis secondary to mycophenolate mofetil in a heart-transplant patient. 2013 Arch. Pathol. Lab. Med. pmid:24168511
Papadea C and Lage JM Immunosuppressants testing in transplantation. 2004 Arch. Pathol. Lab. Med. pmid:15578873
Linder MW and Elin RJ Implications of methodologic bias for therapeutic drug monitoring. 1999 Arch. Pathol. Lab. Med. pmid:10506447
Deschler DG et al. Posttransplantation lymphoproliferative disorder in patients under primary tacrolimus (FK 506) immunosuppression. 1995 Arch. Otolaryngol. Head Neck Surg. pmid:7544136
Moura Penteado LA et al. Evaluation of the effect of tacrolimus on periodontitis induced in rats. 2017 Arch. Oral Biol. pmid:28399470
Gürkan A et al. Alpha 2 integrin gene (ITGA2) polymorphism in renal transplant recipients with and without drug induced gingival overgrowth. 2014 Arch. Oral Biol. pmid:24581850
Gürkan A et al. Gingival crevicular fluid transforming growth factor-beta1 in cyclosporine and tacrolimus treated renal transplant patients without gingival overgrowth. 2008 Arch. Oral Biol. pmid:18342291
Guimarães MR et al. Protective effects of Tacrolimus, a calcineurin inhibitor, in experimental periodontitis in rats. 2007 Arch. Oral Biol. pmid:17367747
Cota LO et al. Gingival overgrowth in cyclosporine, tacrolimus, or sirolimus-based immunosuppressive regimens and the single nucleotide IL-6 (-174 G/C) gene polymorphism. 2010 Arch. Oral Biol. pmid:20430366
Emingil G et al. GCF and serum myeloperoxidase and matrix metalloproteinase-13 levels in renal transplant patients. 2010 Arch. Oral Biol. pmid:20637451
Türkoğlu O et al. Are antimicrobial peptides related to cyclosporine A-induced gingival overgrowth? 2015 Arch. Oral Biol. pmid:25555253
Liang L et al. Long-term outcomes of keratolimbal allograft for total limbal stem cell deficiency using combined immunosuppressive agents and correction of ocular surface deficits. 2009 Arch. Ophthalmol. pmid:19901207
Murphy CC et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. 2005 Arch. Ophthalmol. pmid:15883282
Okada AA Noninfectious uveitis: a scarcity of randomized clinical trials. 2005 Arch. Ophthalmol. pmid:15883289
John SS et al. Chronic localized fibrosing vasculitis of the eyelid. 2009 Arch. Ophthalmol. pmid:19822864
Orange D et al. Cellular immune suppression in paraneoplastic neurologic syndromes targeting intracellular antigens. 2012 Arch. Neurol. pmid:22566506
Parashos SA et al. Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience. 2009 Arch. Neurol. pmid:19597081
Horne SM and Young KD Escherichia coli and other species of the Enterobacteriaceae encode a protein similar to the family of Mip-like FK506-binding proteins. 1995 Arch. Microbiol. pmid:7540828
García-Roca P et al. CYP3A5 polymorphism in Mexican renal transplant recipients and its association with tacrolimus dosing. 2012 Arch. Med. Res. pmid:22704849
Saner FH et al. Severe neurological events following liver transplantation. 2007 Arch. Med. Res. pmid:17174727
Lenz O and Contreras G Treatment options for severe lupus nephritis. 2004 Sep-Oct Arch. Immunol. Ther. Exp. (Warsz.) pmid:15507877
Nowaczyk M et al. 2-Chlorodeoxyadenosine: lack of synergism with cyclosporine A and tacrolimus (FK 506). 1995 Arch. Immunol. Ther. Exp. (Warsz.) pmid:8744655
Campo JV et al. Tacrolimus toxic reaction associated with the use of nefazodone: paroxetine as an alternative agent. 1998 Arch. Gen. Psychiatry pmid:9819077
Deckers-Kocken JM and Pasmans SG Successful tacrolimus (FK506) therapy in a child with pyoderma gangrenosum. 2005 Arch. Dis. Child. pmid:15851442
Hofman T et al. Tacrolimus ointment does not affect the immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity in children. 2006 Arch. Dis. Child. pmid:16798785